Nyxoah (NASDAQ:NYXH) PT Lowered to $16.00 at Cantor Fitzgerald

Nyxoah (NASDAQ:NYXH) had its price target lowered by investment analysts at Cantor Fitzgerald from $17.00 to $16.00 in a report issued on Wednesday, Benzinga reports. The firm presently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price would suggest a potential upside of 98.51% from the stock’s current price.

Several other equities research analysts also recently issued reports on the company. Oppenheimer dropped their price objective on Nyxoah from $15.00 to $13.00 and set an “outperform” rating on the stock in a report on Wednesday. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Nyxoah in a report on Wednesday. Finally, Stifel Nicolaus lowered their price target on Nyxoah from $27.00 to $19.00 and set a “buy” rating for the company in a report on Monday, June 24th. Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, Nyxoah currently has a consensus rating of “Buy” and an average target price of $17.20.

Nyxoah Stock Up 2.2 %

NYXH stock traded up $0.17 during midday trading on Wednesday, hitting $8.06. 4,035 shares of the company’s stock were exchanged, compared to its average volume of 44,654. The company has a current ratio of 3.94, a quick ratio of 3.70 and a debt-to-equity ratio of 0.13. Nyxoah has a 12-month low of $4.00 and a 12-month high of $20.00. The firm has a 50 day moving average price of $8.38 and a 200-day moving average price of $10.58. The stock has a market capitalization of $201.02 million, a price-to-earnings ratio of -4.91 and a beta of 1.44.

Nyxoah (NASDAQ:NYXH) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.45) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.45). Nyxoah had a negative return on equity of 42.14% and a negative net margin of 843.49%. The company had revenue of $1.33 million for the quarter, compared to the consensus estimate of $1.20 million. On average, analysts anticipate that Nyxoah will post -1.72 EPS for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Nyxoah stock. Ikarian Capital LLC acquired a new stake in Nyxoah S.A. (NASDAQ:NYXH) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 50,699 shares of the company’s stock, valued at approximately $684,000.

About Nyxoah

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company's lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.